[Prospects of using latanoprost, prostaglandin F2 alpha analog, in hypotensive therapy for glaucoma].
Hypotensive efficacy and tolerance of a new antiglaucoma drug lathanoprost, a 0.005% xalathane solution, prostaglandin F2 alpha analog, is studied. A single instillation of xalathane decreased ophthalmic tone in normal subjects and glaucoma patients with increased intraocular pressure. Combination of the drug with other hypotensive agents (pilocarpine + timolol) amplified their hypotensive effects. Long (3 months) follow-up showed that xalathane efficacy is comparable to that of pilocarpine and timolol combination but it is tolerated much better.